ASH and EHA Jointly Announce Translational Research Training in Hematology Program
BERLIN, June 5 /PRNewswire-USNewswire/ -- In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create ...
ASH and EHA jointly announce translational research training in hematology program
(BERLIN, June 5, 2009) In an effort to foster global biomedical research that will ultimately lead to new and improved treatments for patients with blood diseases, the American Society of Hematology (ASH) and the European Hematology Association (EHA) have collaborated to create the Translational ...
Ireland's EHA Soft Solutions Selected to Supply Risk Management and Mitigation Software to Quality Employment Credentialing for Healthcare Workforce
CORK, Ireland and WASHINGTON, March 17 /PRNewswire/ --- EHA
Soft Solutions (EHA), an Ireland-based provider of advanced software solutions to the healthcare, oil and gas, telecommunications and other industry segments, today announced that it has been selected by Quality Employment Credentialing (...
Third-Party Audits: EHA Consulting Group Releases Comments on Food Safety Consultant Auditors' Qualifications and Competencies EHA
Consulting Group ( http://www.ehagroup.com ), which has over 25 years of experience providing food safety consulting, released comments today about the qualifications and competencies of food safety auditors.
(PRWEB) February 11, 2009 -- EHA
Consulting Group ( http:...
Micromet, Inc. Reports Second Quarter 2009 Financial Results
... treated at lower doses (167 days versus 83 days).
On June 8, The German Multicenter ALL Study Group (GMALL) presented data at the eha
meeting in Berlin indicating that blinatumomab had achieved the primary endpoint in a phase 2 clinical trial in the treatment of ALL patients. The pr...
ChemGenex's omacetaxine may provide first viable treatment option for highly resistant form of CML
...mGenex's Chief Medical Officer Dr. Adam Craig will host an investor conference call and webcast to discuss the clinical results from both ASCO and the eha
Congress on Thursday 11th of June at 10 am AEST. Details of this event will be advised in coming days.
Public School Alliance Names Plan Advocate to Evaluate Services
...as direct questions to the appropriate party.
selected Kurt Genrich as its Plan Advocate based o... boards. Genrich will lead a team that will enable eha
Strengthen two-way communi...ual association conferences and provide updates at eha
board and executive meetings
Establish a q...
European blood researchers receive award to pursue research opportunities in US
...ce. The fellowship, which encourages increased collaboration between scientists, also grants recipients additional travel stipends to attend both the eha
and ASH annual meetings.
Dr. Alinari, of the Sragnoli Institute of Hematology and Medical Oncology in Italy, will pursue his research project, Ro...
EHA in Medical Technology
TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.
Vion Pharmaceuticals Announces Presentation of Data of Cloretazine(R) (VNP40101M) in Elderly Patients with High-Risk Myelodysplastic Syndromes at the EHA Annual Meeting
NEW HAVEN, Conn., June 13 /PRNewswire-FirstCall/ -- VION
PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from a
previously conducted Phase II trial of its lead anticancer agent
Cloretazine(R) (VNP40101M) in elderly patients with acute myelogenous
leukemia (AML) and high-risk m...
Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
SOUTH SAN FRANCISCO, Calif., May 28 /PRNewswire-FirstCall/ -- Sunesis
Pharmaceuticals, Inc. (Nasdaq: SNSS ) will present data from ongoing
clinical trials of voreloxin (formerly SNS-595) at two major upcoming
Updated interim data from Sunesis' ongoing Phase 2 clinical ...
Vion Pharmaceuticals Presents Clinical Data from a Phase II Trial
of Cloretazine (VNP40101M) in Elderly AML Patients with Unfavorable
Cytogenetics at EHA Meeting
NEW HAVEN, Conn., June 11, 2007 /PRNewswire-FirstCall/ -- Vion
Pharmaceuticals, Inc. announced that it presented clinical data in
a poster session at the 12th Congress of the European Hematology
Association (EHA) Meeting in Vienna, Austria on its lead anticancer
agent Cloretazine(R) (VNP40101M) as...
Clavis Pharma Presented Preliminary Clinical Data on Elacyt at EHA
OSLO, Norway, 11 June 2007 - Clavis Pharma (OSE: CLAVIS)
presented an update of data from its ongoing clinical Phase I/II
study with ELACYT in hematologic cancers during a poster session at
the Annual Meeting of the European Hematology Association (EHA) in
Vienna. ELACYT is a novel cytotoxic agent...
Micromet's Blinatumomab Achieves Primary Endpoint in Phase 2 Study with Acute Lymphoblastic Leukemia Patients
...sease (MRD) in patients with B precursor
acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II
study. 14th Congress of the eha
2009, abstract no. 482
Micromet will host a webcast/conference call this morning from 9:00 am to 11:00 am U.S...
Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
...onse on initial treatment, demonstrating an important unmet need(6).
The proof-of-concept, open-label, single-arm, multicen...olimus in Relapsed Non-Hodgkin's Lymphoma (NHL) and Hodgkin's Disease (HD). eha
14th Congress. Berlin, Germany
National Cancer Institute. Genera...
Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis
The data were highlighted in an oral presentation to the eha
by Anita Hill, MB, ChB, Consultant Hematologist at Bradford Teachi...se, which
include disabling fatigue," said Dr. Hill. "The data presented at eha
us to understand that fatigue in PNH is tied much more closely to hemo...
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
...mias later this year. SGI-1776 may become the first drug in this class
of inhibitors to enter the clinic."
SuperGen's schedule of presentations at eha
is as follows:
Date Time (PDT) Abstract # and Title
Friday, June 13 8:45 a.m.-10 a.m. #744 - A potent small ...
Fractionated Radioimmunotherapy With (90)Y-epratuzumab in
Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II
...ny focused on
developing monoclonal antibodies to treat cancer and other serious
diseases, today announced that data presented at the 12th Congress
in Vienna, Austria, showed positive responses in patients
with non-Hodgkin's lymphoma (NHL) treated with a new
radioimmunotherapy (RAIT) using epratuz...
EHA in Biological Technology
Micromet to Host Conference Call and Webcast to Discuss Blinatumomab Data Presented at EHA on June 8, 2009
BETHESDA, Md., June 2 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a webcast on June 8, 2009 to discuss the blina...
Micromet to Present New Clinical Data on Blinatumomab at EHA and on Adecatumumab at ASCO
Activity of Blinatumomab in NHL and ALL Highlighted at the 14th Congress of the European Hematology Association (EHA)
Adecatumumab Combination Data in Breast Cancer to Be Presented at the American Society of Clinical Oncology (ASCO) Meeting
BETHESDA, Md., May 20 /PRNewswire-FirstCall/ --...
Micromet Receives European Orphan Drug Designation for Treatment of Acute Lymphoblastic Leukemia with BiTE Antibody Blinatumomab
...imal residual disease (MRD) in patients with B precursor acute lymphoblastic leukemia (ALL): Update of an ongoing Phase II study. 14th Congress of the eha
2009, abstract no. 482
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for...
Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
...d molar ratio cytarabine-daunorubicin for patients with advanced leukemia. eha
Harasym T, Lim W, Tardi P, et al. Leukemia cell-se...un) mediated by CPX-351 liposome injection in the bone marrow compartment. eha